Kurmann Partners Develop Interactive Map of Manufacturing Sites

News
Article

The M&A advisory firm has developed an interactive map of manufacturing sites to give insight into the market size of global manufacturing.

Mergers and acquisitions (M&A) advisory firm Kurmann Partners developed an interactive map of manufacturing sites with FDA and European Medicines Agency (EMA) approvals in the manufacturing, analysis, packaging, and distribution of pharmaceuticals.

Each dot on the map represents a manufacturing permit and is placed at the approximate location of the corresponding site. Permits can be filtered by type, site geography, and governing authority (EMA or FDA). Sites can be selected by governing body, type of approval, and keyword. Regions can be selected by zooming in, with full details on record revealed by hovering the mouse over a dot.

According to the company, the map was developed to give insight into the global market size of outsourced and in-house manufacturing. Included in the 24,000 listed manufacturing sites are sites that possess both FDA and EMA permits.

Data for the map was extracted from FDA’s website in March 2017, as well as EMA’s EUDRA website, and were geocoded using Google’s geocoding service.

Source: Kurmann Partners

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments